Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190523 | 0.90 | HDAC3 (0.54) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10993023 | 0.89 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL9706454 | 0.88 | HDAC3 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7227453 | 0.87 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7281346 | 0.86 | HDAC3 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL307790 | 0.85 | MEN1 (0.62) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL10356619 | 0.83 | KDR (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6923968 | 0.83 | HDAC3 (0.67) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11371462 | 0.83 | HDAC3 (0.58) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL7822207 | 0.81 | HDAC3 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021443-B2 | Charged ion channel blockers and methods for use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200377459-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-12-03 | — | — | US | disclosed |
| WO-2017024037-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-1140803-B1 | ((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY | MERCK PATENT GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-6518458-B1 | ((aminoiminomethyl)amino)alkane-carboxamide type in the treatment of pathologies associated with insulin resistance syndrome. | MERCK PATENT GMBH (DE) | 2003-02-11 | — | — | US | disclosed |
| EP-1140803-A1 | ((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY | MERCK PATENT GmbH (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042001-A1 | ((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY | MERCK PATENT GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
| CN-1109057-A | Imidazopyridazine | MERCK PATENT GMBH (DE) | 1995-09-27 | — | — | CN | disclosed |
| US-5025013-A | Antiarrhythmia or antifibrillatory agents | RHONE-POULENC SANTE (FR) | 1991-06-18 | — | — | US | disclosed |
| US-4855497-A | Novel diamine derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1989-08-08 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0196648-A1 | Novel diamine derivatives | Chugai Seiyaku Kabushiki Kaisha (JP) | 1986-10-08 | — | — | EP | disclosed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4558129-A | Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade | SYNTEX (U.S.A.) INC. (US) | 1985-12-10 | — | — | US | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0126449-A1 | Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry | SYNTEX (U.S.A.) INC. (US) | 1984-11-28 | — | — | EP | disclosed |
| US-4415587-A | Method of use of antiarrhythmic 1-arylcarbamoylalkyl imidazole derivatives, composition | BERLEX LABORATORIES, INC. (US) | 1983-11-15 | — | — | US | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
| US-4353921-A | Antiarrythmic 1-arylcarbamoylalkyl-2-imidazoline derivatives, composition and method of use | BERLEX LABORATORIES, INC. (US) | 1982-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377459-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPA1 | HDAC3 818/4885HDAC4 1510/4885HDAC1 1665/4885 |
| US-11021443-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPA1 | HDAC3 818/4885HDAC4 1510/4885HDAC1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.